The MEK inhibitor trametinib is effective in inhibiting the growth of canine oral squamous cell carcinoma

The MEK inhibitor trametinib is effective in inhibiting the growth of canine oral squamous cell carcinoma

Abstract Oral tumors are relatively common in dogs, and canine oral squamous cell carcinoma (COSCC) is the most prevalent oral malignancy of epithelial origin. COSCC is locally aggressive with up to 20% of patients showing regional or distant metastasis at the time of diagnosis. The treatment of cho...

Full description

Saved in:
Bibliographic Details
Main Authors: William P. Katt, Cheryl E. Balkman, Scott D. Butler, Michael Byron, Patrick C. Carney, Amy B. Todd-Donato, Matthew E. Drozd, Gerald E. Duhamel, Jacquelyn M. Evans, Nadine Fiani, Jordan C. Ford, Jennifer K. Grenier, Jessica J. Hayward, Kristiina Heikinheimo, Kelly R. Hume, Elizabeth S. Moore, Rishi Puri, Skylar R. Sylvester, Sydney L. Warshaw, Suzin M. Webb, Andrew C. White, Alexandra L. Wright, Richard A. Cerione, Santiago Peralta
Format: Article
Language:English
Published: Nature Portfolio 2025-02-01
Series:Scientific Reports
Subjects:
Oral squamous cell carcinoma
Canine cancer
Trametinib
RAS signaling
Online Access:https://doi.org/10.1038/s41598-025-90574-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-90574-3

Similar Items